Asperuloside Improves Obesity and Type 2 Diabetes through Modulation of Gut Microbiota and Metabolic Signaling

Anna Nakamura,Yoko Yokoyama,Kazuki Tanaka,Giorgia Benegiamo,Akiyoshi Hirayama,Qi Zhu,Naho Kitamura,Taichi Sugizaki,Kohkichi Morimoto,Hiroshi Itoh,Shinji Fukuda,Johan Auwerx,Kazuo Tsubota,Mitsuhiro Watanabe
DOI: https://doi.org/10.1016/j.isci.2020.101522
IF: 5.8
2020-09-01
iScience
Abstract:Asperuloside (ASP) is an iridoid glycoside that is extracted from <i>Eucommia</i> leaves. <i>Eucommia</i> is used in traditional Chinese medicine and has a long history of benefits on health and longevity. Here, we investigated the impact of ASP on obesity-related metabolic disorders and show that ASP reduces body weight gain, glucose intolerance, and insulin resistance effectively in mice fed with a high-fat diet (HFD). Intestinal dysbiosis is closely linked with metabolic disorders. Our data indicate that ASP achieves these benefits on metabolic homeostasis by reversing HFD-induced gut dysbiosis and by changing gut-derived secondary metabolites and metabolic signaling. Our results indicate that ASP may be used to regulate gut microbiota for the treatment of obesity and type 2 diabetes.
multidisciplinary sciences
What problem does this paper attempt to address?